1. |
Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: Profiles, trends, and determinants. Chin Med J (Engl), 2022, 135(5): 584-590.
|
2. |
de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med, 2020, 382(6): 503-513.
|
3. |
Walter JE, Heuvelmans MA, de Jong PA, et al. Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: Analysis of data from the randomised, controlled NELSON trial. Lancet Oncol, 2016, 17(7): 907-916.
|
4. |
Howington JA, Blum MG, Chang AC, et al. Treatment of stage Ⅰ and Ⅱ non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013, 143(5 Suppl): e278S-e313S.
|
5. |
Kuroda H, Sakata S, Takahashi Y, et al. Subsegmental resection preserves regional pulmonary function: A focus on thoracoscopy. Thorac Cancer, 2021, 12(7): 1033-1040.
|
6. |
Iwata H, Shirahashi K, Mizuno Y, et al. Feasibility of segmental resection in non-small-cell lung cancer with ground-glass opacity. Eur J Cardiothorac Surg, 2014, 46(3): 375-379.
|
7. |
Qu X, Wang K, Zhang T, et al. Long-term outcomes of stageⅠ NSCLC (≤3 cm) patients following segmentectomy are equivalent to lobectomy under analogous extent of lymph node removal: A PSM based analysis. J Thorac Dis, 2017, 9(11): 4561-4573.
|
8. |
Altorki NK, Yip R, Hanaoka T, et al. Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules. J Thorac Cardiovasc Surg, 2014, 147(2): 754-762.
|
9. |
Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): A multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet, 2022, 399(10335): 1607-1617.
|
10. |
Mattioli S, Ruffato A, Puma F, et al. Does anatomical segmentectomy allow an adequate lymph node staging for cT1a non-small cell lung cancer? J Thorac Oncol, 2011, 6(9): 1537-1541.
|
11. |
Ma W, Zhang ZJ, Li Y, et al. Comparison of lobe-specific mediastinal lymphadenectomy versus systematic mediastinal lymphadenectomy for clinical stage T1aN0M0 non-small cell lung cancer. J Cancer Res Ther, 2013, 9 Suppl 2: S101-5.9-2.
|
12. |
Ishiguro F, Matsuo K, Fukui T, et al. Effect of selective lymph node dissection based on patterns of lobe-specific lymph node metastases on patient outcome in patients with resectable non-small cell lung cancer: A large-scale retrospective cohort study applying a propensity score. J Thorac Cardiovasc Surg, 2010, 139(4): 1001-1006.
|
13. |
Chida M, Minowa M, Karube Y, et al. Worsened long-term outcomes and postoperative complications in octogenarians with lung cancer following mediastinal lymph-node dissection. Interact Cardiovasc Thorac Surg, 2009, 8(1): 89-92.
|
14. |
Allen MS, Darling GE, Pechet TT, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg, 2006, 81(3): 1013-1019.
|
15. |
Rahim MK, Okholm TLH, Jones KB, et al. Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell, 2023, 186(6): 1127-1143.
|
16. |
Cerfolio RJ, Bryant AS, Minnich DJ. Complete thoracic mediastinal lymphadenectomy leads to a higher rate of pathologically proven N2 disease in patients with non-small cell lung cancer. Ann Thorac Surg, 2012, 94(3): 902-906.
|
17. |
Cao J, Xu J, He Z, et al. Prognostic impact of lymphadenectomy on outcomes of sublobar resection for stage ⅠA non-small cell lung cancer≤2 cm. J Thorac Cardiovasc Surg, 2018, 156(2): 796-805.
|
18. |
Handa Y, Tsutani Y, Mimae T, et al. Appropriate extent of lymphadenectomy in segmentectomy: A multicenter study. Jpn J Clin Oncol, 2021, 51(3): 451-458.
|
19. |
Wang X, Cao L, Li S, et al. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer. J Cancer, 2019, 10(26): 6703-6710.
|
20. |
Wei B, Jin X, Lu G, et al. A novel nomogram to predict lymph node metastasis in cT1 non-small-cell lung cancer based on PET/CT and peripheral blood cell parameters. BMC Pulm Med, 2023, 23(1): 44.
|
21. |
Mandaliya H, Jones M, Oldmeadow C, et al. Prognostic biomarkers in stageⅣ non-small cell lung cancer (NSCLC): Neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). Transl Lung Cancer Res, 2019, 8(6): 886-894.
|
22. |
Song B, Shi P, Xiao J, et al. Utility of red cell distribution width as a diagnostic and prognostic marker in non-small cell lung cancer. Sci Rep, 2020, 10(1): 15717.
|
23. |
Chen JL, Wu JN, Lv XD, et al. The value of red blood cell distribution width, neutrophil-to-lymphocyte ratio, and hemoglobin-to-red blood cell distribution width ratio in the progression of non-small cell lung cancer. PLoS One, 2020, 15(8): e0237947.
|
24. |
Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer. Lancet, 2021, 398(10299): 535-554.
|
25. |
Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol, 2015, 10(9): 1243-1260.
|
26. |
Tsutani Y, Murakami S, Miyata Y, et al. Prediction of lymph node status in clinical stage ⅠA squamous cell carcinoma of the lung. Eur J Cardiothorac Surg, 2015, 47(6): 1022-1026.
|
27. |
Huang L, Li W, Zhao L, et al. Risk factors of lymph node metastasis in lung squamous cell carcinoma of 3 cm or less in diameter. Medicine (Baltimore), 2017, 96(29): e7563.
|
28. |
Fan J, Yao J, Si H, et al. Frozen sections accurately predict the IASLC proposed grading system and prognosis in patients with invasive lung adenocarcinomas. Lung Cancer, 2023 Apr: 178: 123-130.178-123.
|
29. |
Xu L, Su H, Hou L, et al. The IASLC proposed grading system accurately predicts prognosis and mediastinal nodal metastasis in patients with clinical stage Ⅰ lung adenocarcinoma. Am J Surg Pathol, 2022, 46(12): 1633-1641.
|
30. |
李淼, 王长利. 中央型和周围型肺鳞癌患者淋巴结转移的影响因素分析. 天津医药, 2018, 46(6): 635-639.
|
31. |
Dezube AR, Mazzola E, Deeb A, et al. Mandatory nodal evaluation during resection of clinical T1a non-small cell lung cancers. Ann Thorac Surg, 2022, 113(5): 1583-1590.
|
32. |
Wang K, Xue M, Qiu J, et al. Genomics analysis and nomogram risk prediction of occult lymph node metastasis in non-predominant micropapillary component of lung adenocarcinoma measuring ≤ 3 cm. Front Oncol, 2022, 12: 945997.
|